Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

European Commission defiant over Von der Leyen’s Pfizer texts

EU executive defends its right not to keep records of president’s messages after rebuke from ombudsman

The Guardian - UK

South Korea approves first homemade COVID-19 vaccine

Health officials in South Korea have approved the country's first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic

The Independent UK

Detroit makes COVID vaccines available for children 6 months to 5 years

DETROIT — The city is providing COVID vaccines from Pfizer and Moderna for children ages 6 months up to 5 years of age, following emergency authorization from the federal Food and Drug Administration and approval from the state health department.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Tribune News Service

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

Benzinga

US grapples with whether to modify COVID vaccine for fall

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match the latest changes of the shape-shifting coronavirus

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

US Covid-19 vaccine rollout for under-fives must overcome hesitancy

For many parents the availability of vaccination to the youngest age group is not before time but others plan to ‘wait and see’

The Guardian - US

Pfizer’s omicron booster improves immune response, company says

Pfizer’s two omicron-focused booster vaccines massively improve a person’s immune response against the COVID variant, the company said Saturday.

Tribune News Service

Pfizer says its tweaked COVID-19 shots boost protection against the omicron variant

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

WEKU

Pfizer says tweaked COVID-19 shots boost omicron protection

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection

The Independent UK

Misinformation will be rampant when it comes to COVID-19 shots for young children – here's what you can do to counter it

When the Centers for Disease Control and Prevention endorsed both the Pfizer-BioNTech and Moderna COVID-19 vaccines for all children ages 6 months to 5 years on June 18, 2022, it opened the door for nearly 20 million children to get vaccinated.

The Conversation

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17

The Independent UK

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

The Philadelphia Inquirer

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Editorial: Now let’s get Florida’s children vaccinated against COVID-19

America’s fight against COVID-19 reached another milestone Tuesday as the nation’s youngest children became eligible for the vaccine. This was a long-awaited moment that should bring relief to millions of American families. Now parents need to do their part by taking this opportunity to protect their children, their households and…

Benzinga

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

Los Angeles Times

2 million California kids are now eligible for COVID vaccine. How many will get it?

LOS ANGELES — Jonah Stein exited the vaccination clinic in his father’s arms Tuesday afternoon, proud to show off his Band-Aid.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

Here's a roundup of top developments in the biotech space over the last 24 hours:

WEKU

COVID vaccines are finally here for young kids. But the logistics aren't easy

NPR talks to Claire Hannan, who has helped navigate vaccine rollouts in all 50 states, about some of the challenges involved in quickly getting shots out to millions of young kids.

Reuters

COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown

Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted.

Salon

Does Paxlovid work against COVID?

Experts explain how the drug works, where it came from, and what kinds of side effects to expect

Benzinga

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Tribune News Service

Editorial: On kids’ vaccines, DeSantis is wrong, but never in doubt

The quip “often wrong, never in doubt” fits Gov. Ron DeSantis like a glove. He takes it to extremes by doubling down, at the expense of our children, on his cultivated political appeal to the anti-vaxxer element of right-wing America.

1 … 45 46 47 48

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

336 stories

Centers for Disease Control and Prevention

314 stories

Pfizer Inc

312 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.